BigThink Launches Breast Cancer Patient Symptom Management App ‘WEPEACH TM’

[Asia Economy Reporter Jang Hyowon] BigThink Therapeutics, a bio-pharmaceutical subsidiary of KPS (CEO Han Mikyung), unveiled the app ‘WEPEACH TM’ on the 20th, designed to assist breast cancer patients in managing their symptoms. This app is available for free download on the Google and Apple app stores.

WEPEACH is software developed to support the health management of breast cancer patients, featuring key functions within the app such as ▲My Condition Records ▲Add Visit Schedule ▲Add Medication Information ▲Symptom Management Guidelines ▲Bulletin Board. Professors Han Deokhyun and Kim Sunmi from the Department of Psychiatry at Chung-Ang University, along with Professor Kim Mingyun from the Department of Breast Surgery, provided consultation during the app’s development process.

WEPEACH is planned to be used in conjunction with Neratinib, a breast cancer treatment expected to receive domestic approval around October. Neratinib (Nerlynx®) is the first extended adjuvant oral therapy that reduces the risk of recurrence and brain metastasis in HER2-positive breast cancer and has been sold in the United States since 2017. BigThink secured exclusive domestic commercialization rights last May through a contract with Puma Biotechnology, the developer of Neratinib.

CEO Han Mikyung stated, “In the case of WEPEACH, we are discussing expanding development into DTx for mental disorders through analysis of related data such as symptoms and psychological states of breast cancer patients. We plan to increase the number of DTx products as well as anticancer drugs to create synergy between the two business areas.”

BigThink is preparing exploratory clinical trials in the United States for ‘OCCFree,’ the country’s first digital therapeutic for obsessive-compulsive disorder (OCD). On the 15th (local U.S. time), they completed the IRB (Institutional Review Board) application for the exploratory clinical trial of OCCFree and plan to recruit OCD patients aged 18 and older in three U.S. regions next month.